Does Linda Bain’s Form 3 show any Autolus Therapeutics share purchases or sales?

The data shows no reported buy or sell transactions. All entries are classified as holdings of “Share Option (right to buy)” with zero buy and sell counts in the transaction summary, indicating this filing is an initial statement of existing option positions rather than new market trades.

Autolus director Linda Bain reports option holdings

Q: What does Linda Bain’s Form 3 for Autolus Therapeutics (AUTL) disclose?

The Form 3 discloses that director Linda Bain holds several stock options over Autolus Therapeutics American Depositary Shares. It lists each option’s exercise price, expiration date, and underlying share amount, providing a snapshot of her derivative equity position as of the reporting date.

Q: How many Autolus Therapeutics ADSs are covered by Linda Bain’s largest option grant?

The largest reported option grant covers 105,000 American Depositary Shares with an exercise price of 2.3800 per share. Other grants cover 80,000 and 20,000 ADSs at lower and higher exercise prices, giving her a range of potential equity exposure across several future expiration dates.

Q: Are any of Linda Bain’s Autolus Therapeutics options already vested and exercisable?

Yes. A footnote states that one option is “fully vested and exercisable”, meaning all underlying ADSs can be purchased at the stated exercise price. Another option is scheduled to vest in twelve equal monthly installments starting on July 26, 2025, increasing her exercisable position over time.

Q: What vesting schedule is described for one of Linda Bain’s Autolus options?

One option is described as vesting in twelve equal monthly installments beginning on July 26, 2025. This means the right to purchase the underlying American Depositary Shares increases each month over a one-year period, creating a gradual build-up of exercisable options rather than a single cliff vest.

Autolus Therapeutics plc director Linda Bain filed an initial ownership report showing multiple option awards over American Depositary Shares.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Autolus Therapeutics plc director Linda Bain filed an initial ownership report showing multiple option awards over American Depositary Shares. The holdings include options over 105,000 ADSs at an exercise price of 2.3800, 80,000 ADSs at 3.4800, and additional grants with exercise prices up to 30.2400. Footnotes indicate one option is fully vested and exercisable, while another vests in twelve equal monthly installments commencing on July 26, 2025.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Bain Linda

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--
holding	Share Option (right to buy)	--	--	--

Holdings After Transaction: Share Option (right to buy) — 366,397 contracts (Direct)

Footnotes (2)

F1. Fully vested and exercisable.
F2. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Linda Bain’s Form 3 for Autolus Therapeutics (AUTL) disclose?

The Form 3 discloses that director Linda Bain holds several stock options over Autolus Therapeutics American Depositary Shares. It lists each option’s exercise price, expiration date, and underlying share amount, providing a snapshot of her derivative equity position as of the reporting date.

How many Autolus Therapeutics ADSs are covered by Linda Bain’s largest option grant?

The largest reported option grant covers 105,000 American Depositary Shares with an exercise price of 2.3800 per share. Other grants cover 80,000 and 20,000 ADSs at lower and higher exercise prices, giving her a range of potential equity exposure across several future expiration dates.

Are any of Linda Bain’s Autolus Therapeutics options already vested and exercisable?

Yes. A footnote states that one option is “fully vested and exercisable”, meaning all underlying ADSs can be purchased at the stated exercise price. Another option is scheduled to vest in twelve equal monthly installments starting on July 26, 2025, increasing her exercisable position over time.

When do Linda Bain’s Autolus Therapeutics option grants expire?

The disclosed options have staggered expiration dates running from June 21, 2028 through June 26, 2035. Each grant lists a specific expiration date, so the rights to buy the underlying American Depositary Shares must be exercised, if at all, before those respective deadlines.

What vesting schedule is described for one of Linda Bain’s Autolus options?

One option is described as vesting in twelve equal monthly installments beginning on July 26, 2025. This means the right to purchase the underlying American Depositary Shares increases each month over a one-year period, creating a gradual build-up of exercisable options rather than a single cliff vest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 07:53 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bain Linda

(Last)

(First)

(Middle)

C/O AUTOLUS THERAPEUTICS PLC

THE MEDIAWORKS, 191 WOOD LN, WHITE CITY

(Street)

LONDON

W12 7FP

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Autolus Therapeutics plc [ AUTL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Option (right to buy)	⁽¹⁾	06/21/2028	American Depositary Shares	31,397	$17	D
Share Option (right to buy)	⁽¹⁾	03/28/2029	American Depositary Shares	25,000	$30.24	D
Share Option (right to buy)	⁽¹⁾	06/18/2030	American Depositary Shares	12,500	$13.25	D
Share Option (right to buy)	⁽¹⁾	06/18/2031	American Depositary Shares	12,500	$7.57	D
Share Option (right to buy)	⁽¹⁾	06/28/2032	American Depositary Shares	20,000	$2.84	D
Share Option (right to buy)	⁽¹⁾	06/30/2033	American Depositary Shares	105,000	$2.38	D
Share Option (right to buy)	⁽¹⁾	06/28/2034	American Depositary Shares	80,000	$3.48	D
Share Option (right to buy)	⁽²⁾	06/26/2035	American Depositary Shares	80,000	$2.32	D

Explanation of Responses:

1. Fully vested and exercisable.

2. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.

	/s/ Linda Bain	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR